多药性与老年中风后住院患者的肠道微生物群多样性的改变有关
Ayaka Matsumoto1, Yoshihiro Yoshimura1, Hidetaka Wakabayashi2
1Center for Sarcopenia and Malnutrition Research, Kumamoto Rehabilitation Hospital, Kumamoto 869-1106, Japan.
Clinical nutrition ESPEN
|October 25, 2025
概括
多药,或服用多种药物,与老年中风患者的肠道微生物群多样性减少有关. 这凸显了在为这个人群开处方时需要监测肠道健康的必要性.
科学领域:
- 微生物组研究的研究.
- 老年医学 老年医学
- 神经学 神经学
背景情况:
- 肠道微生物群的多样性影响健康,包括新陈代谢和营养.
- 多药性在老年人中很常见,并且与不良结果有关.
- 多药对老年中风后患者肠道微生物群的影响尚不清楚.
研究的目的:
- 调查多药与肠道微生物群多样性之间的关联.
- 专注于经历过中风的老年人.
主要方法:
- 对156名中风后住院患者 (≥65岁) 的横截面研究.
- 多药学定义为≥5种处方药.
- 便DNA的元基因组分析以评估α多样性 (香农指数,OTU丰富度,Faith的PD).
- 多重线性回归调整为混因子.
主要成果:
- 69.9%的患者表现出多药性 (中位数为6种药物).
- 多药学独立地与香农多样性指数的下降有关 (β = -0.202,p = 0.019).
- 没有发现与观察到的OTU或Faith的PD有显著的关联.
结论:
- 多药性与老年中风后患者的肠道微生物群的定性变化有关.
- 观察到量化和遗传学多样性的潜在负面趋势.
- 强调考虑多药店在中风护理中的肠道微生物群影响.
相关概念视频
Drug Dosing: Geriatric Patients
222
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
222
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
195
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
195
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
228
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
228
Pharmacodynamics in Geriatric Patients: Effects of Age
185
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
185
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
224
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
224
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
233
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
233


